Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259620 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
A Phase 3 study, sponsored by Maruho Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 491
- Enrollment target
NCT03259620: Completed Phase 3 study, sponsored by Maruho Co..
NCT03259620 is a Phase 3 study that has completed, run by Maruho Co.. The registered enrollment target is 491 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03259620, a Phase 3 study, has completed, sponsored by Maruho Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 491 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
Interventions
- DRUG CLS006
- DRUG CLS006 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2018-11-07 |
| Phase | Phase 3 |
What the finished NCT03259620 record still lists
NCT03259620 is an interventional study that assigns participants to a tested intervention. The registered 491 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which CLS006 is the first listed.
NCT03259620 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03259620 about?
NCT03259620 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts". To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
What is the current status of trial NCT03259620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 491 participants. The study started on 2017-10-30. Estimated completion is 2018-11-07.
What interventions are being tested in trial NCT03259620?
The interventions under investigation include: CLS006 (DRUG), CLS006 Vehicle (DRUG).
Who is sponsoring clinical trial NCT03259620?
This trial is sponsored by Maruho Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03259620's enrollment target sits among peer trials
491 781st of 2000 higher than 1,219 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI